(ILM1) Medios - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A1MMCC8
ILM1: Cancer, Neurology, Autoimmune, Eye, Infection, Hemophilia Medications
Medios AG, a leading specialty pharmaceutical company based in Berlin, Germany, focuses on the distribution and manufacturing of high-quality medications tailored to specific patient needs. Since its establishment in 2016, the company has grown significantly, expanding its services and reinforcing its market position through strategic initiatives. Medios operates through two core segments: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment specializes in oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia, offering a broad range of critical medications. The Patient-Specific Therapies segment provides customized solutions, including cytostatic infusions, antibody therapies, and parenteral nutrition, catering to individual patient requirements. This segment also supports clinical trials with investigational medicinal products, underscoring Medios commitment to innovation and patient care.
As a key player in the healthcare sector, Medios AG has built a reputation for reliability and precision in the production and delivery of complex pharmaceuticals. The companys state-of-the-art facilities and adherence to stringent regulatory standards ensure the highest quality of its products. Medios AGs strategic focus on niche therapeutic areas and personalized medicine positions it as a valuable partner for healthcare providers and pharmacies across Germany. With a strong foundation in Berlin, the company continues to explore opportunities for growth and expansion in the specialty pharmaceutical market, driven by its mission to improve patient outcomes through innovative and tailored healthcare solutions.
Additional Sources for ILM1 Stock
ILM1 Stock Overview
Market Cap in USD | 350m |
Sector | Healthcare |
Industry | Medical Distribution |
GiC Sub-Industry | Health Care Distributors |
IPO / Inception |
ILM1 Stock Ratings
Growth 5y | -64.6% |
Fundamental | 23.9% |
Dividend | 0.0% |
Rel. Strength Industry | -9.25 |
Analysts | - |
Fair Price Momentum | 10.50 EUR |
Fair Price DCF | 25.84 EUR |
ILM1 Dividends
No Dividends PaidILM1 Growth Ratios
Growth Correlation 3m | 32.5% |
Growth Correlation 12m | -60% |
Growth Correlation 5y | -89% |
CAGR 5y | -11.33% |
CAGR/Max DD 5y | -0.16 |
Sharpe Ratio 12m | -1.05 |
Alpha | -34.35 |
Beta | 0.45 |
Volatility | 39.77% |
Current Volume | 24k |
Average Volume 20d | 57.2k |
As of March 17, 2025, the stock is trading at EUR 12.76 with a total of 24,019 shares traded.
Over the past week, the price has changed by -1.69%, over one month by -6.73%, over three months by +6.87% and over the past year by -8.07%.
Neither. Based on ValueRay Fundamental Analyses, Medios is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.89 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ILM1 as of March 2025 is 10.50. This means that ILM1 is currently overvalued and has a potential downside of -17.71%.
Medios has no consensus analysts rating.
According to ValueRays Forecast Model, ILM1 Medios will be worth about 11.6 in March 2026. The stock is currently trading at 12.76. This means that the stock has a potential downside of -9.25%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 26.3 | 105.7% |
Analysts Target Price | - | - |
ValueRay Target Price | 11.6 | -9.2% |